ImmunityBio (IBRX) Competitors $2.53 +0.03 (+1.20%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$2.55 +0.02 (+0.79%) As of 05:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBRX vs. VRNA, RVMD, RGC, MRUS, GRFS, RYTM, CYTK, RNA, ABVX, and AXSMShould you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Regencell Bioscience (RGC), Merus (MRUS), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Avidity Biosciences (RNA), Abivax (ABVX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. ImmunityBio vs. Its Competitors Verona Pharma PLC American Depositary Share Revolution Medicines Regencell Bioscience Merus Grifols Rhythm Pharmaceuticals Cytokinetics Avidity Biosciences Abivax Axsome Therapeutics ImmunityBio (NASDAQ:IBRX) and Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment. Do insiders and institutionals believe in IBRX or VRNA? 8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. 76.8% of ImmunityBio shares are held by company insiders. Comparatively, 4.8% of Verona Pharma PLC American Depositary Share shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend IBRX or VRNA? ImmunityBio currently has a consensus target price of $10.75, suggesting a potential upside of 324.90%. Verona Pharma PLC American Depositary Share has a consensus target price of $109.00, suggesting a potential upside of 1.95%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities analysts plainly believe ImmunityBio is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83Verona Pharma PLC American Depositary Share 1 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.07 Which has more risk & volatility, IBRX or VRNA? ImmunityBio has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Verona Pharma PLC American Depositary Share has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Is IBRX or VRNA more profitable? Verona Pharma PLC American Depositary Share has a net margin of -36.62% compared to ImmunityBio's net margin of -648.57%. ImmunityBio's return on equity of 0.00% beat Verona Pharma PLC American Depositary Share's return on equity.Company Net Margins Return on Equity Return on Assets ImmunityBio-648.57% N/A -113.86% Verona Pharma PLC American Depositary Share -36.62%-21.12%-9.07% Does the media prefer IBRX or VRNA? In the previous week, Verona Pharma PLC American Depositary Share had 9 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for Verona Pharma PLC American Depositary Share and 2 mentions for ImmunityBio. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.30 beat ImmunityBio's score of 0.89 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verona Pharma PLC American Depositary Share 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, IBRX or VRNA? Verona Pharma PLC American Depositary Share has higher revenue and earnings than ImmunityBio. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunityBio$14.74M162.25-$413.56M-$0.48-5.27Verona Pharma PLC American Depositary Share$42.28M217.94-$173.42M-$0.99-107.99 SummaryImmunityBio beats Verona Pharma PLC American Depositary Share on 9 of the 17 factors compared between the two stocks. Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBRX vs. The Competition Export to ExcelMetricImmunityBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.36B$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-5.2721.5785.3527.60Price / Sales162.25271.49539.78202.41Price / CashN/A47.1237.9261.55Price / Book-4.4410.1413.016.76Net Income-$413.56M-$52.31M$3.30B$275.88M7 Day Performance1.20%5.14%4.34%2.81%1 Month Performance-1.56%14.68%9.49%9.24%1 Year Performance-23.80%30.98%84.83%35.42% ImmunityBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBRXImmunityBio2.6507 of 5 stars$2.53+1.2%$10.75+324.9%-28.1%$2.36B$14.74M-5.27590VRNAVerona Pharma PLC American Depositary Share1.9614 of 5 stars$106.75+0.0%$109.00+2.1%N/A$8.73B$221.67M-107.8230News CoveragePositive NewsAnalyst ForecastRVMDRevolution Medicines4.2719 of 5 stars$46.60-0.2%$74.64+60.2%-3.9%$8.71BN/A-10.35250Analyst ForecastRGCRegencell Bioscience0.505 of 5 stars$15.42-0.2%N/AN/A$7.63BN/A0.0010News CoveragePositive NewsMRUSMerus1.0934 of 5 stars$94.08-0.1%$92.88-1.3%+78.1%$7.12B$36.13M-17.1137Analyst ForecastHigh Trading VolumeGRFSGrifols3.7682 of 5 stars$10.00+0.4%$10.30+3.1%+9.9%$6.87B$7.81B8.5423,822Positive NewsAnalyst ForecastRYTMRhythm Pharmaceuticals3.5249 of 5 stars$99.74-1.2%$106.64+6.9%+108.4%$6.62B$156.29M-33.11140Positive NewsAnalyst ForecastCYTKCytokinetics3.7433 of 5 stars$54.65-0.6%$75.71+38.5%+11.9%$6.53B$85.74M-10.70250Trending NewsAnalyst ForecastInsider TradeRNAAvidity Biosciences2.2228 of 5 stars$43.65+0.2%$68.32+56.5%+4.2%$6.37B$10.90M-12.26190Analyst ForecastInsider TradeABVXAbivax2.9196 of 5 stars$83.73-1.4%$102.14+22.0%+847.5%$6.31BN/A0.0061Analyst ForecastAXSMAxsome Therapeutics4.782 of 5 stars$122.18+0.6%$177.93+45.6%+40.0%$6.11B$495.03M-24.16380Trending NewsAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies VRNA Alternatives RVMD Alternatives RGC Alternatives MRUS Alternatives GRFS Alternatives RYTM Alternatives CYTK Alternatives RNA Alternatives ABVX Alternatives AXSM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IBRX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
